Company intelligence / Profile preview
Judo Bio
Cambridge, Massachusetts, United Statesjudo.bio ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
01
Overview
Judo Bio has completed preclinical studies demonstrating successful receptor-mediated delivery of oligonucleotides to specific kidney cells using proprietary ligand-siRNA conjugates. These have shown gene silencing of disease-modifying targets in animal models. The company has not yet disclosed clinical results as it remains preclinical.
- Therapeutic areas
- Metabolic DisordersEndocrinologyRheumatologyCardiovascularNephrology
- Modalities
- oligonucleotides (specifically ligand-siRNA conjugates)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Judo Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Judo Bio.